In Segment A, individuals will get different doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Further members will probably be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be offered as "increase-on" therapy. In Phase C, https://abbv-744-therapeutic-pote46891.yomoblog.com/38361199/abbv-744-in-combination-with-immunotherapy-an-overview